RESEARCH TRIANGLE PARK, NC – July 12, 2012 – To help biopharmaceutical companies enter the rapidly growing Brazilian biopharmaceutical market, Quintiles today announced the opening of its Global Commercial Solutions business in Brazil, offering customized sales forces, market penetration strategies and product solutions.
The move into Brazil is part of Quintiles’ strategy to help biopharma companies expand into growing emerging markets while managing costs and risk. Quintiles recently announced Global Commercial Solutions expansion into Russia, and the Middle East and North Africa (MENA) region. Brazil is the world’s fifth most populous country, with a population of about 205 million and a biopharmaceutical market valued at $17.1 billion.
Leading the business in Brazil will be General Manager Vera Valente, based in Quintiles’ offices in Sao Paulo. Most recently, Valente was a director at Interfarma (the Brazilian Pharmaceutical Research Companies Association), where she was responsible for both the Innovation Program and the Market Access Group.
“Brazil is an increasingly important and growing commercial market, and we’re eager to help our customers enter this market in a way that manages risks and increases the probability of success,” said James Featherstone, Senior Vice President of Global Commercial Solutions for Quintiles. “Vera’s experience and relationships in both corporate and government settings in Brazil will help customers navigate the country’s commercialization landscape. This is vital as we work with customers to achieve faster market access and sustained success in this rapidly growing country and region.”
Prior to joining Interfarma, Valente was responsible for the design and implementation of Brazil’s generic drugs policy while serving with Brazil’s National Health Surveillance Agency, Anvisa. During her 14 years in the biopharmaceutical industry she also promoted the development of the Brazilian pharmaceutical industry in her role as Executive Director of the Brazilian Generic Pharmaceutical Association (Pró Genéricos).
Valente said: “Brazil undoubtedly represents a huge untapped opportunity for the biopharmaceutical industry, however, as with any new market, there are challenges. I am delighted to be part of the Quintiles team that will partner with the industry as we endeavor to get new and better medicines to patients.”
Quintiles is the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide. Our network of more than 25,000 professionals in 60 countries has an eye on the future while delivering results today with an unwavering commitment to patients, safety and ethics. Quintiles helps biopharmaceutical companies develop and commercialize products to improve and lengthen patients’ lives while demonstrating value to stakeholders. Visit www.quintiles.com for more information and www.quintiles.com/news for additional company news.